First Hawaiian Bank Buys 4,494 Shares of Humana Inc. (NYSE:HUM)

First Hawaiian Bank grew its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 55.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,647 shares of the insurance provider's stock after buying an additional 4,494 shares during the period. First Hawaiian Bank's holdings in Humana were worth $3,209,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. State Street Corp boosted its stake in Humana by 1.0% during the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider's stock worth $1,701,582,000 after acquiring an additional 53,272 shares during the last quarter. FMR LLC boosted its position in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Pzena Investment Management LLC grew its holdings in shares of Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider's stock valued at $793,830,000 after buying an additional 187,903 shares during the period. Marshall Wace LLP increased its position in shares of Humana by 118.9% in the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider's stock valued at $532,564,000 after buying an additional 774,085 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in Humana by 2.1% during the 2nd quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider's stock worth $442,396,000 after buying an additional 24,842 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

NYSE:HUM traded up $1.01 on Wednesday, hitting $268.22. The company's stock had a trading volume of 892,275 shares, compared to its average volume of 1,165,933. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a one year low of $213.31 and a one year high of $462.08. The stock has a fifty day moving average of $272.86 and a two-hundred day moving average of $311.86. The firm has a market capitalization of $32.30 billion, a P/E ratio of 23.76, a price-to-earnings-growth ratio of 2.12 and a beta of 0.55.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Research analysts predict that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.32%. Humana's dividend payout ratio (DPR) is presently 31.36%.

Analysts Set New Price Targets

Several brokerages have issued reports on HUM. Barclays increased their price target on Humana from $250.00 to $253.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Bank of America upgraded shares of Humana from an "underperform" rating to a "neutral" rating and raised their target price for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. UBS Group reduced their price target on shares of Humana from $380.00 to $250.00 and set a "neutral" rating for the company in a report on Friday, October 4th. Oppenheimer dropped their price objective on shares of Humana from $400.00 to $280.00 and set an "outperform" rating on the stock in a report on Thursday, October 3rd. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $395.00 target price on shares of Humana in a research note on Tuesday, October 1st. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Humana has an average rating of "Hold" and a consensus target price of $302.00.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company's stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.32% of the company's stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.